SIGUIENTE ... : " IDEAYA BIOSCIENCES HA INICIADO UNA COLABORACIÓN CLÍNICA Con ASTRAZENECA " Para Probar el Conjugado Anticuerpo-Fármaco en Fase de Investigación IDE849 , Dirigido Contra la Proteína DLL3 TOP1 , Junto Con el Inhibidor de PD-L1 DURVALUMAB ( IMFINZI de ASTRAZENECA ) , en PACIENTES con SMALL CELL LUNG CANCER EXTENSIVE-STAGE .... ¿ PORQUE NO ELIGIERON AL ATEZOLIZUMAB ... ?
01 diciembre 2008
Spanish Government Has Increased Subsidies for R&D and Scientific Infrastructure .
... This is exactly what Madrid-based Noscira, formerly Neuropharma, is doing. The company is a spin-off from Zeltia. Its focus is on using the library of marine compounds isolated by PharmaMar to look for compounds to treat neurodegenerative diseases. Using this library, Zeltia has isolated several promising drug candidates and currently has two (NP-12 and NP-61) in clinical development to treat Alzheimer’s Disease ...